An adaptive randomized phase II trial to determine pathologic complete response with the addition of carboplatin with and without ABT-888 to standard chemotherapy in the neoadjuvant treatment of triple-negative breast cancer.

Authors

Tiffany P. Avery

Thomas Jefferson University, Philadelphia, PA

Tiffany P. Avery , Adam C. Berger , Albert J. Kovatich , Hallgeir Rui , Terry Hyslop , Edith P. Mitchell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer.

First Author: Kenji Tamura

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).

First Author: Charles E. Geyer Jr.

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC).

First Author: Gunter Von Minckwitz

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320).

First Author: Priyanka Sharma